52.7 F
New York
Monday, November 28, 2022

Date:

Share:

Swiss Life Sciences Group Develops Cannabis Genetics for Healthcare

Related Articles

ClinicalPURSUIT Offers Free Demonstration to Help Clinical Research Understand Their System and How It Can Help During Clinical Trials

Clayton, MO, November 25, 2022 --(PR.com)-- Clinical trials are expensive to conduct but are also essential in modern medicinal and therapeutic development. There is a...

ClinicalPURSUIT’s Software Offers Interactive Randomization Technology and RTSM to Help Researchers Conduct Flawless Clinical Research

Clayton, MO, November 25, 2022 --(PR.com)-- Clinical trials are crucial to developing modern medicines and therapeutic treatments. These research and trials are expected to be...

ClinicalPURSUIT’s Configurable Dashboards Assists Researchers in Conducting Clinical Research

Clayton, MO, November 25, 2022 --(PR.com)-- Clinical trials are fundamental to the success of modern medicinal and therapeutic development. However, there is a great need...

Swiss Life Sciences Group Plc (SLSG) is pleased to announce its partnership with Switzerland’s leading cannabis and CBD genetics experts, Bio Zu Farm.

Press Release



updated: Aug 20, 2021


Swiss Life Sciences Group Plc (SLSG) is pleased to announce its partnership with Switzerland’s leading cannabis and CBD genetics experts, Bio Zu Farm, who have been developing their own cannabis genetics for more than 25 years. Bio Zu are now the owners of leading cannabis strains such as BZ1, one of Europe’s most popular strains, which is being widely grown in every EU country and enjoyed by millions of consumers globally.

SLSG and its Swiss subsidiary, Savim SA, are developing specific proprietary strains of cannabis, with a focus on various areas, but particularly on future medical treatments for a variety of illnesses and…

Read more…

Popular Articles